AMZN   3,202.75 (+0.63%)
NVDA   419.27 (-0.26%)
CGC   17.40 (+8.62%)
MU   50.63 (+1.30%)
AMD   55.91 (-2.36%)
T   30.09 (+1.86%)
ACB   11.96 (+1.61%)
F   6.10 (+4.28%)
GILD   76.34 (+2.17%)
DIS   119.22 (+2.05%)
BAC   24.00 (+5.40%)
BA   178.31 (+2.90%)
AMZN   3,202.75 (+0.63%)
NVDA   419.27 (-0.26%)
CGC   17.40 (+8.62%)
MU   50.63 (+1.30%)
AMD   55.91 (-2.36%)
T   30.09 (+1.86%)
ACB   11.96 (+1.61%)
F   6.10 (+4.28%)
GILD   76.34 (+2.17%)
DIS   119.22 (+2.05%)
BAC   24.00 (+5.40%)
BA   178.31 (+2.90%)
AMZN   3,202.75 (+0.63%)
NVDA   419.27 (-0.26%)
CGC   17.40 (+8.62%)
MU   50.63 (+1.30%)
AMD   55.91 (-2.36%)
T   30.09 (+1.86%)
ACB   11.96 (+1.61%)
F   6.10 (+4.28%)
GILD   76.34 (+2.17%)
DIS   119.22 (+2.05%)
BAC   24.00 (+5.40%)
BA   178.31 (+2.90%)
AMZN   3,202.75 (+0.63%)
NVDA   419.27 (-0.26%)
CGC   17.40 (+8.62%)
MU   50.63 (+1.30%)
AMD   55.91 (-2.36%)
T   30.09 (+1.86%)
ACB   11.96 (+1.61%)
F   6.10 (+4.28%)
GILD   76.34 (+2.17%)
DIS   119.22 (+2.05%)
BAC   24.00 (+5.40%)
BA   178.31 (+2.90%)
Log in

NASDAQ:LNTHLantheus Stock Price, Forecast & News

$14.35
-0.01 (-0.07 %)
(As of 07/10/2020 03:56 PM ET)
Add
Compare
Today's Range
$14.00
Now: $14.35
$14.43
50-Day Range
$12.28
MA: $13.91
$15.00
52-Week Range
$8.67
Now: $14.35
$29.04
Volume23,166 shs
Average Volume1.16 million shs
Market Capitalization$570.56 million
P/E Ratio23.15
Dividend YieldN/A
Beta1.26
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures to assess blood flow to the muscle of the heart; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical used in the manufacture of sources for the calibration and maintenance of single-photon emission computed tomography imaging cameras. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. The company sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Read More
Lantheus logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.90 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LNTH
CUSIPN/A
Phone978-671-8001

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$347.34 million
Cash Flow$1.56 per share
Book Value$2.92 per share

Profitability

Net Income$31.67 million

Miscellaneous

Employees488
Market Cap$570.56 million
Next Earnings Date7/23/2020 (Estimated)
OptionableOptionable

Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.

Lantheus (NASDAQ:LNTH) Frequently Asked Questions

How has Lantheus' stock been impacted by COVID-19 (Coronavirus)?

Lantheus' stock was trading at $13.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LNTH shares have increased by 5.4% and is now trading at $14.35. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Lantheus?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Lantheus.

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Lantheus.

How were Lantheus' earnings last quarter?

Lantheus Holdings Inc (NASDAQ:LNTH) announced its quarterly earnings results on Thursday, April, 30th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.29 by $0.07. The medical equipment provider earned $90.70 million during the quarter, compared to the consensus estimate of $91.70 million. Lantheus had a net margin of 7.13% and a return on equity of 46.94%. The firm's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.28 earnings per share. View Lantheus' earnings history.

What price target have analysts set for LNTH?

2 analysts have issued twelve-month price targets for Lantheus' shares. Their forecasts range from $29.00 to $29.00. On average, they anticipate Lantheus' share price to reach $29.00 in the next year. This suggests a possible upside of 102.1% from the stock's current price. View analysts' price targets for Lantheus.

Has Lantheus been receiving favorable news coverage?

Headlines about LNTH stock have been trending negative on Friday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lantheus earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Lantheus.

Are investors shorting Lantheus?

Lantheus saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 2,170,000 shares, a decline of 5.2% from the May 31st total of 2,290,000 shares. Based on an average daily trading volume, of 406,900 shares, the days-to-cover ratio is presently 5.3 days. Approximately 5.6% of the company's stock are short sold. View Lantheus' Current Options Chain.

Who are some of Lantheus' key competitors?

What other stocks do shareholders of Lantheus own?

Who are Lantheus' key executives?

Lantheus' management team includes the following people:
  • Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)
  • Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)
  • Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)
  • Dr. Cesare Orlandi, Chief Medical Officer (Age 69)
  • Mr. John J. Bolla, Chief Operating Officer (Age 49)

When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.03%) and Diversified Trust Co (0.03%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View institutional ownership trends for Lantheus.

Which institutional investors are buying Lantheus stock?

LNTH stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., and Diversified Trust Co. View insider buying and selling activity for Lantheus.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $14.35.

How big of a company is Lantheus?

Lantheus has a market capitalization of $570.56 million and generates $347.34 million in revenue each year. The medical equipment provider earns $31.67 million in net income (profit) each year or $1.17 on an earnings per share basis. Lantheus employs 488 workers across the globe.

What is Lantheus' official website?

The official website for Lantheus is www.lantheus.com.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.